Linda Llewelyn Sells 6,441 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,441 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total value of $34,974.63. Following the transaction, the insider now directly owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Linda Llewelyn also recently made the following trade(s):

• On Wednesday, January 15th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The stock was sold at an average price of $5.80, for a total value of $37,363.60.
• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96.

Health Catalyst Trading Down 3.0 %

Shares of NASDAQ:HCAT opened at $5.23 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market capitalization of $318.25 million, a P/E ratio of -3.87 and a beta of 1.34. The business’s 50-day moving average is $6.24 and its 200 day moving average is $7.29. Health Catalyst, Inc. has a 1 year low of $5.20 and a 1 year high of $9.24.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds have recently modified their holdings of HCAT. First Light Asset Management LLC grew its position in Health Catalyst by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock worth $37,055,000 after purchasing an additional 944,631 shares during the last quarter. Impax Asset Management Group plc lifted its stake in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after buying an additional 195,525 shares during the period. Daventry Group LP grew its holdings in shares of Health Catalyst by 3.8% during the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company’s stock valued at $17,742,000 after buying an additional 91,878 shares during the last quarter. Primecap Management Co. CA increased its position in shares of Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after acquiring an additional 25,000 shares during the period. Finally, Alyeska Investment Group L.P. raised its stake in Health Catalyst by 74.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after acquiring an additional 861,150 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Citigroup dropped their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Royal Bank of Canada dropped their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Piper Sandler reduced their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. Wells Fargo & Company dropped their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Finally, KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.20.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.